<DOC>
	<DOCNO>NCT00430820</DOCNO>
	<brief_summary>The study hypothesis differential proteomic technique use discover new circulate biomarkers coronary atherosclerosis blood patient suffer coronary artery disease ( either stable unstable ) compare group patient without coronary artery disease</brief_summary>
	<brief_title>Discovery New Circulating Biomarkers Coronary Atherosclerosis</brief_title>
	<detailed_description>Hypothesis : Our hypothesis coronary atherosclerosis induces quantitative qualitative modification circulate protein , capture differential proteomic approach apply serum plasma sample . Identification modification circulate blood patient coronary artery disease ( versus patient without coronary artery disease ) and/or patient acute coronary syndrome ( versus stable coronary artery disease ) may lead discovery new biomarkers coronary atherosclerosis atherosclerotic plaque vulnerability . Objectives : Primary objective : Identification new circulate biomarkers stable unstable coronary artery disease use new approach differential proteomics . Secondary objective : - Evaluation diagnostic value new biomarkers diagnosis stable unstable coronary artery disease . - Comparison diagnostic value new biomarkers diagnostic value 1 ) validate biomarkers atherosclerosis ( eg , CRP , IL-6 , CD40L , marker leukocyte activation , … ) ; 2 ) non-invasive measure arterial function ( eg , carotid artery intima-media thickness , pulse wave velocity , ankle/brachial index , … ) - Description relationship new biomarkers major adverse coronary event ( death , myocardial infarction , revascularization ) 12-month follow-up . Methods : Uniq center , prospective study . Three group patient study . Group 1 : Non-ST-elevation acute myocardial infarction ; Group 2 : Stable coronary artery disease ; Group 3 : normal coronary artery absence detectable atherosclerotic lesion . A new proteomic approach apply serum plasma sample obtain 1 month index hospitalisation . This approach include 3 step : 1 ) equalisation circulate protein ( expose low-concentration protein belong `` deep-proteome '' ) ; 2 ) Retention chromatography ; 3 ) protein separation use 2D-electrophoresis Surface-Enhanced Laser Desorption/Ionisation Time-of-Flight ( SELDI-TOF ) . Biomarkers high diagnostic value subsequently identify use Matrix-Assisted Laser Desorbtion/Ionisation Time-of-Flight ( MALDI-TOF ) tandem mass spectrometry ( MS/MS ) . Perspectives : Validation diagnostic prognostic value new biomarkers discover identify use proteomic approach describe require development straightforward measurement technique ( eg , ELISA ) , use prospectively retrospectively cohort patient coronary artery disease . Basic study perform parallel , good understand role new biomarkers pathophysiology atherosclerosis .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Group 1 ( NonSTelevation acute myocardial infarction ) : Chest pain le 48 hour admission , And modification STT ( persistent ST elevation ) 12lead EKG , And elevation troponinI &gt; 1xN , And presence ≥1 de novo stenosis ( e ) &gt; 50 % locate ≥1 native coronary artery ( y ) successfully treat use percutaneous coronary intervention stenting . Group 2 ( Stable coronary artery disease ) : Documented myocardial ischemia ( stable angina positive stress test ) And presence ≥1 de novo stenosis ( e ) &gt; 50 % locate ≥1 native coronary artery ( y ) successfully treat use percutaneous coronary intervention stenting . Group 3 ( Normal coronary artery ) : No history coronary artery disease , neurovascular disease peripheral artery disease , And normal coronary angiography perform suspected coronary artery disease And absence significant functional anatomic abnormality suggestive atherosclerosis noninvasive arterial study ( measurement intimamedia thickness , pulse wave velocity , anklebrachial index , … ) . Group 1 : Preexisting EKG abnormality ( include leave bundle branch block ) preclude accurate assessment STT change Group 2 : History acute coronary syndrome Groups 1 2 : Culprit coronary artery stenosis restenosis stent thrombosis locate bypass graft . All group : Heart failure ( NYHA class ≥II ) Left ventricular ejection fraction &lt; 50 % Severe valvular heart disease require surgical percutaneous therapy History autoimmune , inflammatory neoplasia disease ; infectious disease month admission Life expectancy &lt; 1 year Age &lt; 18 year &gt; 80 year Current pregnancy breastfeed Homeless traveler may followedup Refusal sign inform consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Biomarkers</keyword>
	<keyword>Proteomics</keyword>
	<keyword>Mass spectrometry</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Coronary artery disease</keyword>
</DOC>